Overexpression of ecotropic viral integration site-1 is a prognostic factor of lung squamous cell cancer

Xu, Xueliang; Liu, Shengchen; Xia, Jianguo

doi:10.2147/ott.s132410

Cited by 6 publications

(10 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In acute myeloid leukaemia, EVI1 overexpression is an independent adverse prognostic factor [22,23] . Similar results have also been reported in ICC [13] , hepatocellular carcinoma [24] , colorectal cancer [25] , prostate cancer [26] , lung cancer [27] , glioblastoma multiforme [28] and so on [29,30] . These data indicate that EVI1 plays an important role in tumour progression.…”

Section: Discussionsupporting

confidence: 86%

Downregulation of EVI1 Expression Inhibits Cell Proliferation and Induces Apoptosis in Hilar Cholangiocarcinoma via the PTEN/AKT Signalling Pathway

et al. 2020

View full text Add to dashboard Cite

Aims: Hilar cholangiocarcinoma (HCCA) is a tumour with high malignancy, low surgical resection potential, and a poor prognosis. Ecotropic Viral Integration site 1 (EVI1) is a transcriptional regulator that has been proven to be associated with tumourigenesis and progression in many human solid tumours. However, the expression of EVI1 and its role in HCCA progression remain unclear. The aim of this study was to clarify the association between EVI1 expression and clinical outcomes in patients with HCCA. Methods: The expression of EVI1 in HCCA tissue samples and cell lines was examined by quantitative real-time PCR (qRT-PCR), Western blotting, and immunohistochemistry (IHC). Kaplan-Meier analysis was used for survival analysis. A log-rank test was performed for univariate analysis of survival, and a Cox regression model was utilized for multivariate analysis of survival. Cell proliferation was measured by cell counting kit-8 (CCK-8), colony formation, and 5-ethynyl-2'-deoxyuridine (EdU) assays. The cell cycle was evaluated by flow cytometry. Cell apoptosis was detected by flow cytometry and a terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick-end labelling (TUNEL) assay. In vivo tumour growth was observed for xenografts in nude mice. Results: EVI1 expression was upregulated in HCCA tissue samples and correlated with a poor prognosis. In clinical specimens, the expression of EVI1 correlated with tumour histological grade and tumour size. Knocking down EVI1 expression reduced HCCA cell proliferation, blocked cell cycle progression, and promoted apoptosis in vitro and in vivo. Furthermore, we found that EVI1 could regulate the AKT signalling pathway by regulating PTEN levels in HCCA. Conclusion: Our data revealed that EVI1 played important roles in HCCA tumourigenesis and development. Our findings suggest that EVI1 may be a potentially useful therapeutic target in HCCA.

show abstract

Section: Discussionsupporting

confidence: 86%

Downregulation of EVI1 Expression Inhibits Cell Proliferation and Induces Apoptosis in Hilar Cholangiocarcinoma via the PTEN/AKT Signalling Pathway

et al. 2020

View full text Add to dashboard Cite

show abstract

“…High expression of EVI1 was significantly associated with a poorer five-year survival rate of squamous cell lung cancer patients. Moreover, EVI1 was identified as an independent prognostic factor, suggesting that EVI1 alone was enough to predict poor prognosis of squamous cell lung cancer [ 18 ]. Another study done by Wang et al [ 19 ] demonstrated EVI1 overexpression in both estrogen receptor-positive (ER +) and estrogen receptor-negative (ER −) breast carcinomas by analyzing a tissue microarray of 608 breast carcinoma patient specimens.…”

Section: Evi1 and Mds1/evi1 In Solid Tumorsmentioning

confidence: 99%

“…In addition, they identified MECOM expression as an independent prognosis marker in GBM [97]. Xu et al [18] showed that 32.32% of squamous cell lung cancer samples express a high level of EVI1. High expression of EVI1 was significantly associated with a poorer five-year survival rate of squamous cell lung cancer patients.…”

Section: Evi1 and Mds1/evi1 In Solid Tumorsmentioning

confidence: 99%

“…EVI1, MDS1/EVI1 and AML1/MDS1/EVI1 promote leukemogenesis by modulating differentiation, apoptosis, cell cycle and proliferation. EVI1 expression is not only upregulated in leukemia, but also in a number of solid tumors, including colorectal cancer, breast cancer, prostate cancer and ovarian cancer [ 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 ]. EVI1 has been shown to be redistributed or overexpressed in several types of solid tumors.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

EVI1 in Leukemia and Solid Tumors

Liang

Wang

2020

Cancers

View full text Add to dashboard Cite

The EVI1 gene encodes for a transcription factor with two zinc finger domains and is transcriptionally activated in a subset of myeloid leukemias. In leukemia, the transcriptional activation of EVI1 usually results from chromosomal rearrangements. Besides leukemia, EVI1 has also been linked to solid tumors including breast cancer, lung cancer, ovarian cancer and colon cancer. The MDS1/EVI1 gene is encoded by the same locus as EVI1. While EVI1 functions as a transcription repressor, MDS1/EVI1 acts as a transcription activator. The fusion protein encoded by the AML1/MDS1/EVI1 chimeric gene, resulting from chromosomal translocations in a subset of chronic myeloid leukemia, exhibits a similar function to EVI1. EVI1 has been shown to regulate cell proliferation, differentiation and apoptosis, whereas the functions of MDS1/EVI1 and AML1/MDS1/EVI1 remain elusive. In this review, we summarize the genetic structures, biochemical properties and biological functions of these proteins in cancer.

show abstract

“…Moreover, in several solid tumors, an EVI1 overexpression indicates poor survival. Such a correlation between EVI1 overexpression and a poor outcome is described, e. g., for cancers of the colon, lung, ovary, and prostate [8][9][10][11][12][13][14]. But EVI1 is not just a prognostic marker.…”

Section: Introductionmentioning

confidence: 99%

EVI1 as a Marker for Lymph Node Metastasis in HNSCC

Idel

Ribbat‐Idel

Kuppler

et al. 2020

IJMS

View full text Add to dashboard Cite

Background: HNSCC is the sixth most common cancer in humans and has still a very poor prognosis. The treatment methods so far are very often associated with mutilation and impairment in the quality of life. Except for p16 expression, there are no reliable prognostic markers in HNSCC so far. Ecotropic Viral Integration Site 1 (EVI1) is a well-described prognostic marker in leukemia and different types of solid cancers. In these, a high EVI1 expression is associated with a poor prognosis. In HNSCC, it is not known so far if EVI1 has any prognostic relevance. Materials and Methods: We used our representative tissue cohort of 389 primary HNSCCs, of which 57.2% had one or more lymph node metastases. Here EVI1 expression was analyzed via immunohistochemistry and correlated with the clinical characteristics of these patients. Results: Although in HNSCC EVI1 expression does not predict poor survival, a high EVI1 expression in the primary tumor correlates with a lymph node metastatic disease. Conclusion: Consequently, EVI1 may serve as a biomarker to predict an occult lymph node metastasis in a clinical nodal negative (cN0) HNSCC.

show abstract

Overexpression of ecotropic viral integration site-1 is a prognostic factor of lung squamous cell cancer

Cited by 6 publications

References 22 publications

Downregulation of EVI1 Expression Inhibits Cell Proliferation and Induces Apoptosis in Hilar Cholangiocarcinoma via the PTEN/AKT Signalling Pathway

Downregulation of EVI1 Expression Inhibits Cell Proliferation and Induces Apoptosis in Hilar Cholangiocarcinoma via the PTEN/AKT Signalling Pathway

EVI1 in Leukemia and Solid Tumors

EVI1 as a Marker for Lymph Node Metastasis in HNSCC

Contact Info

Product

Resources

About